BMT was carried out on a patient with DiGeorge syndrome who suffered recurrent infections after birth. At 13 months of age, 8.0 × 10 8 /kg of bone marrow nuclear cells were infused from an HLA-identical sibling using only anti-thymocyte globulin to prevent rejection. Donor DNA was not detected on microsatellite polymorphism by PCR. At 19 months of age, a second BMT from the same donor was carried out using busulfan and cyclophosphamide as conditioning. DNA examination of bone marrow showed chimerism at day 18 and complete donor origin at day 28. Seven months post-BMT, the numbers of CD3-, CD4-and CD8-positive cells were in the normal range. BMT is thus an effective therapy for DiGeorge syndrome. Keywords: DiGeorge syndrome; complete type; immunodeficiency; bone marrow transplantation DiGeorge syndrome (DGS) is characterized by dysmorphic faces, congenital heart disease, hypocalcemia and T cell dysfunction due to aplasia of the thymus.
DiGeorge syndrome (DGS) is characterized by dysmorphic faces, congenital heart disease, hypocalcemia and T cell dysfunction due to aplasia of the thymus. 1 Although confirmation of aplasia of the thymus is difficult, it is clinically classified as complete or incomplete; the former manifests with cellular immunodeficiency and the latter does not. 2 Therapies for the immunodeficient type of this syndrome have been fetal thymus transplantation, thymic hormone administration and bone marrow transplantation (BMT). For thymic transplantation, it is necessary to use fetal thymic tissue 3 or to use cultured thymic epithelial tissue, since it is not as easy to get donor cells. For thymic hormones such as thymosin, thymopoietin and thymulin, it is unclear what nature of thymic hormones should be used and over what time period, results have varied. 4 BMT has been attempted for DGS in seven patients 5 and two of these underwent transplantation without any pre-conditioning, with favourable results. 6, 7 Here, we report a patient with complete-type DGS treated with BMT who exhibited reconstitution of T cell immunity.
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Case report
A boy was born at 39 weeks gestation with an Apgar score of 7. His birth weight was 3275 g. There were no special events during gestation except for polyhydramion. Family history was negative. He showed cyanosis after birth and respiratory arrest occurred at day 6 probably due to hypocalcemia, and he was referred to the National Nagasaki Central Hospital. He showed the characteristic facial features such as a hypertelorism, narrowed palpebral fissures, low set ears, deformity of both ear helices, anteverted nostrils, a shortened philtrum, micrognathia and a high arched palate. He had hypocalcemia with a low plasma level of parathyroid hormone. Chest X-ray, ultrasound and computed tomography (CT) showed no thymus-like components. Echocardiogram and cardiac catheterization revealed tetralgy of Fallot. He failed to thrive, and showed a tendency towards infection after admission, including repeated episodes of fever and continuous presence of echo 7 virus in urine samples. Lymphocyte subsets showed a marked decrease in T cells. Thus, he was diagnosed as having DiGeorge syndrome.
Gamma-globulin was infused once a month from 2 months of age, but he suffered aseptic meningitis at 8 months of age and the frequency of the febrile episodes was increased from 12 months of age. He again suffered aseptic meningitis at 13 months of age and was referred to our hospital.
On physical examination at 13 months of age, his weight was 7010 g and height 69.0 cm. He had a submucosal cleft palate, Levine 4 degree heart murmur, cyanosis, and a mild hepatomegaly. The skin showed atopic dermatitis-like eruptions over the whole body and scars were visible. Peripheral lymph nodes were not palpable. He had mild mental retardation.
Laboratory findings around 7 days of age were as follows: red blood cell count 440 × 10 4 /l, white blood cell count 29 800 (neutrophils 89%, lymphocytes 7%, monocytes 4%), platelet count 27.4 × 10 4 /l. Serum C-reactive protein was 2.79 mg/dl. Serum calcium, phosphorus and parathyroid hormone levels were 4.7 mg/dl, 3.7 mg/dl and less than 50 pg/ml, respectively. Serum zinc levels and thyroid function were normal. Fluorescent in situ hybridization with a probe D22S75 on interphase stage lymphocytes showed a loss of one allele at chromosome 22q11.2. His cells were infused. Cyclosporine (CyA) and short-term methotrexate (MTX) were used for GVHD prophylaxis. He had no adverse effects and did not develop GHVD.
Although the percentages of CD3 and CD8 cells increased transiently at day 70, they decreased thereafter to pre-transplantation levels and CD4 numbers did not increase. DNA polymorphism analysis of the patient's bone marrow cells on day 55 showed no donor-derived material (Figure 1a ). At 19 months of age, a second BMT from the same donor was carried out (Figure 2 ). Following conditioning with busulfan (Bu) 4 mg/kg × 4 days and cyclophosphamide (CY) 60 mg/kg × 2 days, 6 × 10 8 /kg donor marrow cells were infused. GVHD prophylaxis was as in the first BMT. On day 18, WBC and neutrophil counts were more than 1000/l and 500/l, respectively. On day 24, the CD4 + cell count exceeded 500/l. Platelet infusions were necessary until day 37. The stimulation index to PHA was increased by more than 10 times compared to pre-BMT. DNA polymorphism analysis of marrow cells revealed chimerism on day 18 and only a donor-derived pattern on day 28 (Figure 1b) . Clinically, the skin eruption improved markedly. Febrile episodes decreased until 2 months post-BMT. However, a lower respiratory tract infection persisted, probably due to bronchial compression resulting from pulmonary artery dilatation and pulmonary valve atresia. He had no acute or chronic GVHD. Now, 7 months post-BMT, FACS 
Discussion
Bone marrow transplantation was carried out for typical, complete-type DiGeorge syndrome. This patient had continuous T-lymphocyte dysfunction, including CD4-positive cell count decrease and a low PHA SI from birth to 13 months of age. Therefore, it was necessary to re-constitute his immunological state. 8 At first BMT, donor marrow cells were rejected. Possible reasons for this rejection are that: (1) ATG acted against the donor cells; (2) there were too many cells in the recipient's marrow to allow engraftment of donor stem cells; (3) preconditioning with only ATG was insufficient because he Table 3 Change of CD45RA-positive cells had normal numbers and function of natural killer cells and residual T cells. Van Leeuwen et al 9 reported that they used only ATG for conditioning in three patients with severe combined immunodeficiency (SCID), but only one patient engrafted, one developed GVHD, and the other failed to engraft. We used 2.5 mg/kg of ATG from day −5 to day −2 and serum ATG concentrations are shown in Table 1 .
At the second BMT, busulfan and cyclophosphamide were used as conditioning. Making physical space by eliminating bone marrow cells with busulfan could permit early increase of donor cells in peripheral blood. 10 Fischer et al, 11 in the European multicenter study of BMT for SCID, described the rate of engraftment as higher with Bu/CY conditioning than without. BMT for DGS has been carried out on seven patients, but the details have been reported in only two patients (Table 2 ). In the case reported by Goldsobel et al 6 T cells had begun to increase 2 weeks after BMT and the number of CD4 cells increased to 281/l. Thymic serum factor (TSF) was increased 5 months after BMT. In the case reported by Borzy et al 7 the acquisition of T cell function was similar to the former case. The present case also developed T cell function after the second BMT. The main difference between the three patients is that engraftment occurred only in T cells in the former two cases, probably due to the difference in conditioning. The implications of this will not become apparent for several years.
The following are possibilities for the effectiveness of BMT in DGS. (1) Induction of thymic differentiation by T cells. Thymic migration and/or differentiation in the patient was abnormal and thymic function was insufficient, resulting in insufficient T cell maturation. Transplantation of mature donor T cells enabled interaction of the T cells and thymic microenvironment; thus, thymic differentiation was induced and maturation of T cells occurred. 12 Extent of abnormal differentiation of the thymus varies from agenesis to ectopic to normal. 13 The thymus was undetectable after BMT by echogram or computed tomography. However, T cells increased in peripheral blood and had characteristics of thymus-derived T cells, such as TCR ␣␤-positivity. Two-color staining FACS analysis showed that the number of CD4 + CD45RA + cells increased gradually and that 25% of CD4-positive cells were CD45RA positive at 9 months post-BMT (Table 3 ). This suggested that at least some of the T cells were thymus derived, because it is thought that in the case of peripheral expansion, T cell increase in peripheral blood reveals the CD4 + CD45RO + phenotype, while in the case of the thymus-dependent pathway CD4 + CD45RA + naive T cells appear. 14 It is difficult to detect an ectopic thymus, so measurement of thymic hormone 15 may be useful in proving its existence. (2) The possibility of expansion of extra thymic T cells. The present case did not reveal any increment of TCR ␥␦-positive cells characteristic of extrathymic T cells before or after BMT, so it is unlikely that the increased cells after BMT were derived from expansion of extra thymic T cells. (3) It is possible that post-thymic precursor cells, which were able to expand in peripheral lymph nodes without contact with the thymus, or long-lived memory T cells were infused from the donor, and that these cells increased by various immunological means. The authors in two former reports 6, 7 argued that expansion of post-thymic precursor cells was most likely after BMT for DGS. As far as the increment of TSF after BMT in the case of Goldsobel et al 6 is concerned, however, activation of the hypoplastic thymus by infused mature T cells may be possible.
The present patient was able to reconstitute his immunological environment after BMT. There are several approaches to treatment of susceptibility to infection in DGS but the results of thymic transplantation for DGS have not been entirely satisfactory on the whole. Thymic transplantation may only offer incomplete immunological reconstitution, and additional infusion of T cells may be necessary. Also, some complete-type DGS patients may have a functionally insufficient thymic remnant, and interaction with infused T cells may activate it. In this context, BMT with pre-conditioning may be one of the therapeutic modalities to consider for DGS.
